Clinical Implications of Understanding Radiographic Findings in Relation to Clinical Outcomes in Rheumatoid ArthritisKEYSTONE, Edward C.Journal of rheumatology. Supplement. 2009, Vol 36, Num 82, pp 11-16, issn 0380-0903, 6 p.Conference Paper

Does Anti-Tumor Necrosis Factor-α Therapy Affect Risk of Serious Infection and Cancer in Patients with Rheumatoid Arthritis?: A Review of Longterm DataKEYSTONE, Edward C.Journal of rheumatology. 2011, Vol 38, Num 8, pp 1552-1562, issn 0315-162X, 11 p.Article

CURRENT TREATMENT OPTIONS AND NEW DIRECTIONS IN THE MANAGEMENT OF RHEUMATOID ARTHRITISSMOLEN, Josef; KEYSTONE, Edward C.Rheumatology (Oxford. Print). 2012, Vol 51, issn 1462-0324, 57 p., SUP5Serial Issue

Tumor necrosis factor-a blockade in the treatment of rheumatoid arthritisKEYSTONE, Edward C.Rheumatic diseases clinics of North America. 2001, Vol 27, Num 2, pp x-xi, issn 0889-857X, 19 p.Article

Biologic Therapies for the Management of Rheumatoid ArthritisKEYSTONE, Edward; HARAOUI, Boulos.Journal of rheumatology. Supplement. 2009, Vol 36, Num 82, issn 0380-0903, 46 p.Conference Proceedings

Optimizing Treatment with BiologicsMADER, Reuven; KEYSTONE, Edward.Journal of rheumatology. Supplement. 2007, Vol 34, Num 80, pp 16-24, issn 0380-0903, 9 p.Article

Tumor Necrosis Factor and Anti-Tumor Necrosis Factor TherapiesKEYSTONE, Edward C; WARE, Carl F.Journal of rheumatology. Supplement. 2010, Vol 37, Num 85, pp 27-39, issn 0380-0903, 13 p.Article

Developing an effective treatment algorithm for rheumatoid arthritisKEYSTONE, Edward C; SMOLEN, Josef; RIEL, Piet Van et al.Rheumatology (Oxford. Print). 2012, Vol 51, issn 1462-0324, v48-v54, SUP5Article

Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatmentEMERY, Paul.Rheumatology (Oxford. Print). 2012, Vol 51, issn 1462-0324, v22-v30, SUP5Article

Assessment and Management of Rheumatoid ArthritisHARAOUI, Boulos.Journal of rheumatology. Supplement. 2009, Vol 36, Num 82, pp 2-10, issn 0380-0903, 9 p.Conference Paper

Comparative Overview of Safety of the Biologics in Rheumatoid ArthritisKHRAISHI, Majed.Journal of rheumatology. Supplement. 2009, Vol 36, Num 82, pp 25-32, issn 0380-0903, 8 p.Conference Paper

Practical Aspects of Therapeutic Intervention in Rheumatoid ArthritisTHOMPSON, Andy.Journal of rheumatology. Supplement. 2009, Vol 36, Num 82, pp 39-41, issn 0380-0903, 3 p.Conference Paper

Unmet Needs in Rheumatoid ArthritisBYKERK, Vivian.Journal of rheumatology. Supplement. 2009, Vol 36, Num 82, pp 42-46, issn 0380-0903, 5 p.Conference Paper

Les atteintes asymétriques des petites articulations dans la polyarthrite rhumatoïde : analyse de la prévalence et de l'évolution vers la symétrie dans le temps = Asymmetry of small joint involvement in rheumatoid arthritis : prevalence and tendency towards symmetry over timeZANGGER, Philippe; KEYSTONE, Edward C; BOGOCH, Earl R et al.Revue du rhumatisme (Ed. française). 2005, Vol 72, Num 5, pp 411-419, issn 1169-8330, 9 p.Article

Biologic monotherapy as initial treatment in patients with early rheumatoid arthritisGOMEZ-REINO, Juan.Rheumatology (Oxford. Print). 2012, Vol 51, issn 1462-0324, v31-v37, SUP5Article

Patient-Driven Outcomes in Rheumatoid ArthritisWELLS, George A.Journal of rheumatology. Supplement. 2009, Vol 36, Num 82, pp 33-38, issn 0380-0903, 6 p.Conference Paper

Relative Efficacies: Antimalarials to Abatacept -The Choice Is OursRUSSELL, Anthony S.Journal of rheumatology. Supplement. 2009, Vol 36, Num 82, pp 17-24, issn 0380-0903, 8 p.Conference Paper

Challenges in Diagnosing Latent Tuberculosis Infection in Patients Treated with Tumor Necrosis Factor AntagonistsKEYSTONE, Edward C; PAPP, Kim A; WOBESER, Wendy et al.Journal of rheumatology. 2011, Vol 38, Num 7, pp 1234-1243, issn 0315-162X, 10 p.Article

Superior efficacy of combination therapy for rheumatoid arthritis : Fact or fiction?SMOLEN, Josef S; ALETAHA, Daniel; KEYSTONE, Edward et al.Arthritis and rheumatism. 2005, Vol 52, Num 10, pp 2975-2983, issn 0004-3591, 9 p.Article

Mechanisms of Action of Tumor Necrosis Factor Antagonists: Canadian Expert Roundtable Meeting, Banff, Alberta, Canada, November 28-30, 2003KEYSTONE, Edward C; DINARELLO, Charles A.Journal of rheumatology. Supplement. 2005, Vol 32, Num 74, issn 0380-0903, 48 p.Conference Proceedings

Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritisCHOY, Ernest.Rheumatology (Oxford. Print). 2012, Vol 51, issn 1462-0324, v3-v11, SUP5Article

From Bedside to Bench: The Role of Anti-Tumor Necrosis Factor Agents in the Management of Immune-Mediated Inflammatory DiseasesHARAOUI, Boulos; KEYSTONE, Edward C; RUSSELL, Anthony S et al.Journal of rheumatology. Supplement. 2010, Vol 37, Num 85, issn 0380-0903, 64 p.Serial Issue

Assessing the safety of biologic agents in patients with rheumatoid arthritisRUBBERT-ROTH, Andrea.Rheumatology (Oxford. Print). 2012, Vol 51, issn 1462-0324, v38-v47, SUP5Article

Is a 12-week trial sufficient to evaluate clinical responses to etanercept or MTX treatment in early RA?KAVANAUGH, Arthur; KEYSTONE, Edward; JINGYUAN FENG et al.Rheumatology (Oxford. Print). 2010, Vol 49, Num 6, pp 1201-1203, issn 1462-0324, 3 p.Article

Current and emerging therapies for Rheumatoid arthritis, with a focus on infliximab: Clinical impact on joint damage and cost of care in canadaRUSSELL, Anthony; HARAOUI, Boulos; KEYSTONE, Edward et al.Clinical therapeutics. 2001, Vol 23, Num 11, pp 1824-1838, issn 0149-2918Article